Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Jan 2006

Millikan Robert C, Heard Kimberley, Winkel Scott, Hill Edgar J, Heard Kristin, Massa Beri, Mayes Lydia, Williams Patricia, Holston Rachel, Conway Kathleen, Edmiston Sharon, de Cotret Allan René

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age of Onset
Share to Black or African American
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to North Carolina

Share to Odds Ratio

Share to Proto-Oncogene Proteins c-mdm2

Share to White People

Source

Identifiers

PMID: 16434608
DOI: 10.1158/1055-9965.EPI-05-0692

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No association between the MDM2 -309 T/G promoter polymorphism and breast cancer in African-Americans or Whites.PMID 16434608Read ↗

Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk.Semantic proximity Read ↗

Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish PopulationSemantic proximity Read ↗

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer.Semantic proximity Read ↗

Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population.Semantic proximity Read ↗

The p53 Arg72Pro and MDM2 -309 polymorphisms and risk of breast cancer in the nurses' health studies.Semantic proximity Read ↗

Assessment of TP53 Polymorphisms and MDM2 SNP309 in Premenopausal Breast Cancer Risk.Semantic proximity Read ↗

MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk.Semantic proximity Read ↗

MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.Semantic proximity Read ↗

No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.